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Background: In novel treatment approaches, therapeutics should be designed to target cancer 
stem cells (CSCs). Quantum dots (QDs) are a promising new tool in fighting against cancer. 
However, little is known about accumulation and cytotoxicity of QDs in CSCs.
Methods: Accumulation and cytotoxicity of CdTe-MPA (mercaptopropionic acid) QDs in 
CSCs were assessed using flow cytometry and fluorescence-activated cell sorting techniques 
as well as a colorimetric cell viability assay.
Results: We investigated the expression of two cell surface-associated glycoproteins, CD44 
and CD133, in four different cancer cell lines (glioblastoma, melanoma, pancreatic, and prostate 
adenocarcinoma). Only the melanoma cells were positive to both markers of CD44 and CD133, 
whereas the other cells were only CD44-positive. The QDs accumulated to a similar extent in 
all subpopulations of the melanoma cells. The phenotypical response after QD treatment was 
compared with the response after ionizing radiation treatment. The percentage of the CD44high-
CD133high subpopulation decreased from 72% to 55%–58% for both treatments. The stem-like 
subpopulation CD44highCD133low/- increased from 26%–28% in the untreated melanoma cells 
to 36%–40% for both treatments.
Conclusion: Treatment of melanoma cells with QDs results in an increase of stem-like cell 
subpopulations. The changes in phenotype distribution of the melanoma cells after the treatment 
with QDs are comparable with the changes after ionizing radiation.
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Introduction
Cancer exhibits intratumoral heterogeneity at the genetic and epigenetic levels. The 
existence of functional heterogeneity between different subpopulations of tumor cells 
has been described in clonogenic and xenotransplantation studies. Defined subpopula-
tions of cancer cells possess enhanced tumorigenicity when injected into immunode-
ficient mice. Such isolated cells with self-renewal potential have been termed cancer 
stem cells (CSCs).1,2
CSCs display extensive differentiation potential and can give rise to new tumors. It 
has been reported that CSCs are more likely to survive chemotherapy or radiotherapy. 
Low efficiency of chemotherapy is associated with the ability of CSCs to extrude a 
drug from the cytosol through transcytosis.3 Other studies have documented that CSCs 
are also more resistant to radiotherapy than nonstem cells.4 Reduced radiosensitivity 
is associated with activated defense mechanisms against radiation-induced reactive 
oxygen species and accelerated repopulation of CSCs. It may also turn out that CSCs are 
located in hypoxic regions, which shift metabolism to glycolysis and   hypoxia-induced 
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radioresistance. The percentage of CSCs within a tumor 
could also be a predicting factor to radiosensitivity or 
chemotherapy.5,6 Enrichment of the stem cell subpopulation 
has been observed in glioma after irradiation.7 Thus, CSCs 
could be the main targets in novel cancer therapies. Creating 
radio- or chemosensitizers that preferentially sensitize CSCs 
could be a new strategy in drug development.
Quantum dots (QDs) are a new class of nanomaterials 
with possibility for easy manipulation of surface chemistry 
and optical or magnetic properties, and are thus suited for 
targeted anticancer therapies. QDs are about 10–100 times 
brighter and 100–1000 times more stable against photo-
bleaching than organic dyes or fluorescent proteins, and the 
optical characteristics of a QD can be tuned by adjusting its 
size.8 It has been reported that QDs can be used for imaging 
of cancer cells ex vivo and for detection of mesenchymal stem 
cells.9,10 The QD surface can be manipulated by either directly 
conjugating them with antibodies and oligonucleotide 
probes or indirect linking by strategies such as streptavidin–
biotin interaction.11 Antibody-conjugated QDs allow specific 
recognition and tracking of plasma membrane antigens. 
Snyder et al12 have used QD-CD44 conjugates for CSC detec-
tion ex vivo. However, it is not known how QDs accumulate 
and influence the expression of CSC surface antigens.
In this study, we investigated the effect of QDs on 
the expression of two putative stem cell markers, plasma 
membrane-associated glycoproteins CD44 and CD133, 
by flow cytometry and fluorescence-activated cell sorting 
(FACS) techniques.
Material and methods
Materials
A pancreatic adenocarcinoma (Mia-PaCa-2) cell line was 
purchased from the Health Protection Agency Culture 
  Collections. Prostate adenocarcinoma (PC3) and glioblastoma 
(U87) cells were obtained from the American Type   Culture 
Collection. Melanoma (FEMX-I) cells were originally 
derived from lymph node metastasis of a patient with mela-
noma at the Norwegian Radiumhospital in 1980.13 CdTe QDs 
coated with mercaptopropionic acid (MPA) were purchased 
from PlasmaChem GmbH (Berlin, Germany) emitting far-red 
fluorescence (λmax = 710 ± 5 nm).
Cell culturing
Mia-PaCa-2 and U87 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM). PC3 and FEMX-I cells 
were cultured in Roswell Park Memorial Institute (RPMI)-
1640 medium. Both growth mediums contained 10% fetal 
bovine serum (FBS, Fisher Scientific, Oslo, Norway), 
100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM 
L-Glutamine (Sigma-Aldrich Norway AS, Oslo, Norway). 
In the case of the U87 cells, the DMEM medium was addi-
tionally supplemented with 3% MEM nonessential amino 
acids (Sigma-Aldrich). The cells were routinely cultivated 
in 25 cm2 Nunclon culture dishes (VWR International, Oslo, 
Norway) under standard conditions and were subcultured 
twice a week and kept in a humidified incubator at 37°C with 
5% CO2. For experiments, the cells were harvested by bring-
ing them into suspension via trypsinization and by seeding a 
necessary amount of cells into Nunclon multiplates.
QD staining
A stock solution of QDs was prepared by dissolving 1 mg 
QDs in 1 mL phosphate buffered saline (PBS) (Sigma-
Aldrich) at pH 7.4 or saline (0.9% w/v NaCl). The stock 
solution was further diluted to a desired concentration in 
the growth medium and poured over the cells growing in 
the multiplates. The medium without QDs was poured in a 
few wells to have control cells in the same multiplate. After 
incubation at 37°C for 24 hours, the cells were washed with 
ice-cold PBS+ (standard PBS supplemented with 0.9 mM 
CaCl2 and 0.5 mM MgCl2 to prevent cell detachment at this 
step) to remove any free QDs. Immediately after washing, 
the cells were brought into suspension by trypsinization for 
further analysis using monoclonal antibodies.
Radiation treatment
Ionizing radiation was used as a positive treatment control 
with changes in the phenotype of cancer cells. FEMX-I cells 
were exposed to different doses ranging from 0 Gy to 10 Gy 
delivered by a Müller X-ray apparatus operated at 220 kV , 
20 mA, with a 0.5 mm Cu filter.
Immunostaining and FACS
Up to 106 cells were labeled in PBS solution with 
mouse antihuman monoclonal CD44 antibody conju-
gated with fluorescein isothiocyanate (FITC, BD Bio-
sciences, Franklin Lakes, NJ) and mouse antihuman 
monoclonal CD133 antibody conjugated with phycoeryth-
rin (PE, eBioscience, San Diego, CA) for 20 minutes 
at room temperature.   Respective mouse immunoglobu-
lin and dye conjugates, IgG2b-FITC (Dako, Glostrup, 
Denmark) and IgG1-PE (BD Biosciences), were used as 
unspecific binding controls. Flow cytometric analysis was car-
ried out with a FACSort or LSR II analyzer (BD   Biosciences). 
The data were analyzed with FlowJo (Tree Star Inc, Ashland, 
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OR) software. A minimum of 10,000 viable cells were 
measured per   sample. Using forward and side scatter   profiles 
and propidium iodide staining, debris, cell doublets, and dead 
cells were gated out, respectively. FACS was performed on a 
BD FACSAria or FACSort Cell Sorter (BD Biosciences). Puri-
ties of the sorted populations, as determined by postsorting 
flow analysis, were generally .90%.
Cytotoxicity assay
The cytotoxicity of the QDs was determined using a methyl-
ene blue assay on the FEMX-I cell line. The same amount of 
cells in each well were seeded in a 96-well plate and incubated 
with different concentrations of the QDs. After 24 hours 
of incubation the old medium was carefully aspirated, and 
the cells were supplemented with fresh medium and left 
for further growth under standard culture conditions. After 
3 days the cells were washed with ice-cold PBS and fixed with 
70% ethanol. After 10 minutes, 100 µL of filtered 1% w/v 
methylene blue aqueous solution was added to each well. 
After 20 minutes, the excess dye was removed by washing the 
wells with distilled water. To elute the dye, 200 µL of 0.2% 
Triton X-100 solution (Sigma-Aldrich) was added to each 
well and left overnight at 37°C. The plates were then gently 
shaken, and the absorbance at 650 nm was measured for each 
well with a microplate photometer (BioTek Instruments, 
Winooski, VT). The photometer was blanked on the first 
column of the wells containing the elution solvent alone. 
For the determination of the FEMX-I cell viability follow-
ing ionizing radiation, the cells were grown for 24 hours 
after irradiation, and cell suspensions were analyzed by a 
Beckman Coulter viability analyzer (Vi-Cell XR, Beckman 
Coulter Inc, Brea, CA).
Results
Heterogeneity of four cancer cell lines using putative stem 
cell markers for CD133 and CD44 was investigated. The cell 
surface-associated CD44 is an adhesion glycoprotein. The 
function of CD133 is still unknown, but it has been shown to 
be involved in the dynamics of membrane protrusions and 
to mark CSCs. The flow cytometry technique was performed 
to detect fluorescence from single cells after combined stain-
ing with antibody-dye conjugates against CD133 and CD44. 
All cell lines expressed CD44 to a similar degree, from 96.2% 
to 99.9% (Figure 1). However, the expression of CD133 
was very low among these cell lines (0.001%–0.23%) with 
slightly higher prevalence in U87 cells (1.94%, Figure 1B). 
Only FEMX-I cells exhibited high levels of CD133 (99.1%, 
Figure 1D).
The response to CD markers was not enough to deter-
mine heterogeneity of the cell lines. Therefore, we further 
analyzed the shape of their phenotypical patterns (Figure 1). 
U87 (Figure 1B) cells show nearly uniform   semihorizontal 
oval-shaped cloud distribution. PC3   (Figure 1A) and 
Mia-PaCa-2 (Figure 1C) cells show two clouds, indicat-
ing two subpopulations: circular-shaped dense cloud 
with high CD44 expression (CD44high) and a horizontal 
oval cloud with low/no CD44 expression (CD44low/-). 
FEMX-I cells appear to consist of three different sub-
populations: CD44highCD133high, CD44highCD133low/-, and 
CD44low/-CD133low/- (Figure 1D).
Because FEMX-I cells showed high expression of 
both CD markers with three distinct subpopulations, we 
further examined their capability of growing and restoring 
initial population. Each subpopulation (CD44highCD133high, 
CD44highCD133low/-, and CD44low/-CD133low/-) was FACS 
sorted, isolated, and plated under usual growing   conditions. 
CD44low/-CD133low/- cells did not grow after sorting. 
CD44highCD133high cells grew after sorting, but after 10 days 
of growth the cells did not show significant changes in their 
phenotypical composition. Immediately after sorting, the 
subpopulation was composed of ∼95% CD44highCD133high 
cells and remained unchanged after 10 days of growth 
 ( Figure 2B), suggesting that CD44highCD133high sub-
population was unable to restore its progeny. However, 
CD44highCD133low/- cells were able to grow and change their 
phenotypical composition. Immediately after sorting, the 
cells were composed of ∼80% CD44highCD133low/- cells, and 
after 10 days of growth this subpopulation was composed 
of ∼58% CD44highCD133low/- and ∼41% CD44highCD133high 
cells, thus approaching the phenotypical composition of the 
unsorted cells (Figure 2C).
To determine treatment effects, first, the survival rate was 
measured for the FEMX-I cells. The cell viability follows a 
dose-response relationship: The proliferation decreases with 
increasing radiation dose or QD concentration (Figure 3). 
Second, phenotypic responses were measured following 
these treatments.
It is important to ensure that changes in phenotypical 
composition are due to the treatment and are not affected 
by wrong gating or background signals. After the radiation 
treatment, morphologic alterations in the cells can be seen, 
such as increased size and roughness (Figure 4A). Cell auto-
fluorescence signal also alters after the treatment. The cells 
show a higher autofluorescence signal on the detector corre-
sponding to CD44-FITC (Figure 4B), which must be included 
as a background signal when gating. The same is true for the 
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Figure 1 The expression of CD133 and CD44 in different human cancer cell lines. Prostate adenocarcinoma (A), glioblastoma (B), pancreatic adenocarcinoma (C), 
and melanoma cells (D). The red dots represent the isotype control and the blue dots represent the stained samples.
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Figure 2 The expression of CD133 and CD44 after fluorescence-activated cell sorting of different subpopulations of FEMX-I cells. Phenotype of the total population of the 
cells before sorting (A), and phenotype of CD44highCD133high (B) and CD44highCD133low/- (C) subpopulations after 10 days’ growth after sorting. The different colors of the 
dots in A, B, and C show the number of overlapping dots: the red dots represent denser areas than the blue dots.
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Figure 3 Viability of FEMX-I cells after different treatments: irradiated with different 
doses of 160 kV X-rays (curve with black quadrates) and incubated with different 
concentrations  of  the  CdTe-MPA  quantum  dots  for  24  hours  (curve  with  white 
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Figure 4 Forward and side scatter chart of the untreated and radiation treated (7 Gy and 10 Gy) FEMX-I cells (A). Flow charts of the same cells without antibody staining 
(autofluorescence) (B) and with CD133/CD44 markers (C). The expression profiles of CD133 and CD44 shown separately for untreated cells (D) and for cells irradiated with 
7 gy (E) and 10 gy (F). The different colors of the dots in D, E, and F show the number of the overlapping dots: The red dots represent denser areas than the blue dots.
detector corresponding to CD133-PE. The addition of the 
surface membrane markers shows changes in phenotypical 
composition caused by the treatment (Figure 4C).
The doses (7 Gy and 10 Gy) of ionizing radiation 
were chosen to induce death of more than half of the cells 
(  Figure 3). The percentage of the CD44highCD133high subpopu-
lation decreased from 72% in the control unirradiated cells to 
58%–62% after irradiation, whereas that of the subpopulation 
CD44highCD133low/- increased from 26% to 35%–36%. The 
percentage of CD44lowCD133low/- subpopulation increased 
from 0.6% in the untreated cells to ∼2.4%–4.4% in the cells 
after irradiation (Figure 4D–F).
To investigate the response of each subpopulation 
to the QDs, a 50 µg/mL concentration of the CdTe-
MPA QDs was chosen to be high enough to induce 
death of approximately half of the cells (Figure 3).   
A doubled concentration of the QDs was also used   
to observe any concentration-dependent processes. 
 The intensity histogram of the infrared detector confirms 
the accumulation of the QDs in the cells (  Figure 5A and B). 
The number of QD positives was calculated as a percent-
age of CD44highCD133high or CD44highCD133low/- cells 
(Figure 5C). Approximately 94%–99% cells in each 
subpopulation exhibited QD fluorescence showing no dif-
ference in the QD uptake by these subpopulations.
After the treatment with the QDs, morphologic   alterations 
in the cells could be seen just like after the ionizing 
  radiation: increased cell size, roughness (Figure 6A), and 
cell autofluorescence (Figure 6B). Again, just like for the 
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Figure 6 Forward and side scatter chart of the untreated and quantum dot-treated FEMX-I cells (A). Flow charts of the same cells without antibody staining (autofluorescence) 
(B) and with CD133/CD44 markers (C). The expression profile of CD133 and CD44 shown separately for untreated cells (D) and for quantum dot-treated cells with two 
concentrations, 50 µg/mL (E) and 100 µg/mL (F). The different colors of the dots in D, E, and F show the number of overlapping dots: The red dots represent denser areas 
than the blue dots.
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Figure 5 Accumulation of the CdTe-MPA quantum dots (QDs) in FEMX-I cells. 
Intensity histograms represent autofluorescence of the control untreated cells (red 
curve) and the fluorescence of the cells treated with 50 µg/mL (A, blue curve) and 
100 µg/mL (B, blue curve) QDs, respectively. The percentage of cells positive for 
QD fluorescence was 94%–99% in all subpopulations (C).
cells treated with the ionizing radiation, the correct gating 
for the background signals was performed (Figure 6C). The 
QD treatment resulted in the appearance of a denser cloud 
of the cell debris (located in the left lower corner in Fig-
ure 6A), confirming that the QDs are cytotoxic to the 
cells. When compared with the control untreated cells, 
the cells treated with the lower concentration of the QDs 
contained 1.4 times more of the CD44highCD133low/- cells 
(39% versus 28% in the control) and 1.3 times less of the 
CD44highCD133high cells (54% versus 72% in the control)   
(Figure 6D and E).
The percentage of CD44low/-CD133low/- cells increased 
after the treatment, which might be associated with QD-
induced early apoptosis. Early apoptotic cells are difficult 
to exclude during dead cell staining with propidium iodide; 
therefore, apoptotic cells might be present in this flow 
cytometry plot. The phenotypical composition observed in 
the cells treated with the higher concentration of the QDs 
(Figure 6F) was analogous to that of the lower concentra-
tion of the QDs. This indicates that concentration-dependent 
changes in the phenotypical composition were not   
observed.
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Discussion
The property of resistance to radiation therapy is one major 
clinical criterion to characterize CSCs. The fraction of 
CSCs in a tumor could be a factor to predict resistance to 
the therapy.5–7 McCord et al14 have studied responsiveness 
to radiation in a series of glioma cell lines. Interestingly, 
the stem cells were more sensitive to radiation than estab-
lished cell lines. The authors have concluded that a major 
determinant of radiosensitivity is the repair of DNA lesions, 
which depends on the tumor origin from which the cells were 
isolated. The mechanisms of CSC responsiveness to existing 
therapies are not yet well understood.
In this study, we have investigated population heterogene-
ity of prostate and pancreatic adenocarcinoma, glioblastoma, 
and melanoma cell lines using putative CSC markers, CD44, 
an adhesion molecule, and CD133, which has recently been 
considered as a common marker of CSCs.15 All studied cell 
lines exhibited high expression of CD44, whereas CD133 
was highly expressed only in FEMX-I cells. Therefore, 
the latter cells were chosen for further examination of their 
stem-like properties.
Our experiments demonstrate that FEMX-I cells 
consist of three distinct subpopulations with different 
CD133 and CD44 expression levels: CD44highCD133high, 
CD44highCD133low/-, and CD44low/-CD133low/-. Hill16 and 
Rappa et al17 have also shown CD133 expression in FEMX-I 
cells and stated that downregulation of CD133 in FEMX-I 
cells results in decreased growth rate and migratory capacity, 
which suggests CD133 to be essential in tumor formation and 
regression. Interestingly, we can suggest that the subpopula-
tion with lower expression of CD133 antigen represents tum-
origenic stem cells, because only CD44highCD133low/- cells 
were capable of progeny restoration after their isolation and 
were also more resistant to the radiation treatment and the 
toxic effect of CdTe-MPA QDs. After the radiation or QD 
treatment, the FEMX-I cells maintained a higher fraction of 
CD44highCD133low/- cells (35%–40%) compared with that 
(26%–28%) in the control untreated cells.
The toxicity of CdTe QDs is associated with release 
of Cd2+ ions and generation of reactive oxygen species 
products.18 The concentration of the QDs was chosen to 
correspond to lethal concentrations of LC40 and LC30, 
ie, high enough to induce obvious QD-associated cell 
death and thus to examine whether a QD-resistant sub-
population exists. Although no significant differences 
in CdTe-MPA accumulation among CD44highCD133high, 
CD44highCD133low/-, and CD44low/-CD133low/-   subpopulations 
were observed, these subpopulations showed   different 
  behavior. The   percentage of CD44highCD133low/- cells   actually 
increased after the QD treatment.
The CD133 was the first identified membrane protein 
named prominin for its prominent location on the protrusion 
of cell membranes.15 Rappa et al17 have suggested that the 
CD133 can be a potential target for antimelanoma therapy. 
In our study, we have divided the CD133+ population into 
two subpopulations, CD133high and CD133low/-, which showed 
different responses to the therapy.
When considering novel targeted therapies it is important 
to know whether a new therapeutic agent can actually accumu-
late in a cell. In this study we show that, although the FEMX-I 
cell line is heterogeneous, the CdTe-MPA QDs accumulate 
equally in different cell subpopulations. To our knowledge, 
this is the first time QD accumulation in different subpopula-
tions of cancer stem-like cells has been evaluated.
The other important aspect is to ensure that the therapeutic 
agent binds to the desired target. Lidke et al19 targeted cancer 
cells by conjugating QDs to a human epidermal growth factor, 
a small protein with a specific affinity to its membrane recep-
tor. Fluorescence emitted from such QDs allowed continuous 
observation of the cells. Wang et al20 demonstrated a CSC 
targeting therapy. Photothermolysis with carbon nanotubes 
conjugated with anti-CD133 antibody selectively eradicated 
CD133 positive glioma cells. Current interest in QDs lies in 
their attractive imaging properties. QDs conjugated with a 
targeting antibody also have the potential to label and eliminate 
desired subpopulations of cancer cells.
Conclusion
Our experiments show that the FEMX-I cell line is heteroge-
neous and can be divided into subpopulations with higher and 
lower expressions of CD44 and CD133. The subpopulation 
with the lower expression of CD133 (CD44highCD133low/-) 
displays characteristics of CSCs. It is more resistant to 
  ionizing radiation or QD cytotoxicity and able to restore its 
progeny. There is no difference in the accumulation of the 
CdTe-MPA QDs among different FEMX-I subpopulations. 
These results encourage further investigations on the appli-
cability of QDs in CSC targeting therapies.
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